Lucas Capital Management reduced its stake in Illumina, Inc. (NASDAQ:ILMN) by 4.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,176 shares of the life sciences company’s stock after selling 50 shares during the period. Lucas Capital Management’s holdings in Illumina were worth $204,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Advocacy Wealth Management Services LLC purchased a new stake in shares of Illumina during the first quarter valued at about $102,000. Advisory Services Network LLC purchased a new stake in shares of Illumina during the first quarter valued at about $117,000. Gemmer Asset Management LLC raised its stake in shares of Illumina by 5.7% in the first quarter. Gemmer Asset Management LLC now owns 686 shares of the life sciences company’s stock valued at $117,000 after buying an additional 37 shares in the last quarter. Patten Group Inc. raised its stake in shares of Illumina by 2.7% in the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock valued at $166,000 after buying an additional 25 shares in the last quarter. Finally, NN Investment Partners Holdings N.V. raised its stake in shares of Illumina by 11.3% in the second quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock valued at $171,000 after buying an additional 100 shares in the last quarter. 93.81% of the stock is owned by institutional investors and hedge funds.

Illumina, Inc. (NASDAQ:ILMN) opened at 194.47 on Monday. Illumina, Inc. has a 12-month low of $119.37 and a 12-month high of $198.55. The firm has a 50-day moving average price of $174.66 and a 200-day moving average price of $171.89. The company has a market cap of $28.39 billion, a P/E ratio of 39.02 and a beta of 0.83.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.68 by $0.14. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The company had revenue of $662 million during the quarter, compared to analysts’ expectations of $642.38 million. During the same quarter in the previous year, the business earned $0.86 EPS. Illumina’s revenue was up 10.3% compared to the same quarter last year. On average, equities research analysts forecast that Illumina, Inc. will post $3.65 earnings per share for the current fiscal year.

WARNING: “Lucas Capital Management Lowers Stake in Illumina, Inc. (ILMN)” was posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/08/07/lucas-capital-management-lowers-stake-in-illumina-inc-ilmn.html.

Several analysts have issued reports on the company. BidaskClub raised Illumina from a “sell” rating to a “hold” rating in a research note on Monday. Zacks Investment Research raised Illumina from a “hold” rating to a “buy” rating and set a $195.00 target price for the company in a research note on Thursday, July 27th. Cowen and Company reaffirmed an “outperform” rating and issued a $200.00 target price on shares of Illumina in a research note on Wednesday, August 2nd. Deutsche Bank AG set a $175.00 target price on Illumina and gave the stock a “hold” rating in a research note on Friday, July 28th. Finally, First Analysis raised Illumina from an “underweight” rating to an “equal weight” rating and set a $176.00 target price for the company in a research note on Wednesday, August 2nd. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have given a buy rating to the stock. Illumina presently has a consensus rating of “Hold” and an average target price of $174.38.

In other Illumina news, SVP Charles Dadswell sold 145 shares of the company’s stock in a transaction on Monday, June 5th. The stock was sold at an average price of $184.75, for a total value of $26,788.75. Following the completion of the sale, the senior vice president now directly owns 10,791 shares in the company, valued at approximately $1,993,637.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Jay T. Flatley sold 20,000 shares of the company’s stock in a transaction on Wednesday, August 2nd. The stock was sold at an average price of $176.43, for a total value of $3,528,600.00. Following the completion of the sale, the director now owns 534,176 shares of the company’s stock, valued at $94,244,671.68. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 156,770 shares of company stock valued at $28,069,728. 1.60% of the stock is owned by company insiders.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.